In 1989, Johnson & Johnson sold its talc subsidiary. Instead of taking the opportunity to transition Johnson’s Baby Powder ...

The study couldn't explain that difference, but Mavromatis noted that differences in blood drug concentration, weight loss, metabolism or hormones could be at play. Excess body weight can raise ...

A new three-drug combination could help women with a common form of aggressive breast cancer live longer, a study has suggested. The trial, which included 325 patients from across 28 countries ...

So researchers have been wondering: Might blockbuster weight-loss drugs like Wegovy, Ozempic and Zepbound also play a role in cancer prevention? Now, a study being presented at a major cancer ...

Overall, the study found, ceasing weight loss drugs is likely to yield a more rapid weight regain than ceasing behavioral weight loss measures, like dieting. In total, 7,944 titles and abstracts ...

Drug discovery is the process through which potential new medicines are identified. It involves a wide range of scientific disciplines, including biology, chemistry and pharmacology. Protein ...

Chinese University medical researchers on Monday said a multinational study they led has found a mainland-developed cancer drug to be effective in treating tumours. They said the drug D3S-001 ...

In the study, researchers analyzed data from 43 U.S. health systems to compare two groups: people with obesity and diabetes who took GLP-1 drugs and other people with the same conditions who took ...

“Our study aims to underscore the benefits of the ... Convenience for patients, improved drug bioavailability, and lower cost. “The traditional drop protocol requires patients to administer ...

EBC-129 is the first made-in-Singapore antibody-drug conjugate (ADC ... Updated clinical data from the ongoing Phase 1 study of EBC-129 will be presented at the 2025 Annual Meeting of the American ...

In response, in 2015 the Food and Drug Administration (FDA ... observed some upward trends in trial representativeness. Our study did not include other racial or ethnic groups or vulnerable ...

Sanofi’s plans to submit itepekimab to regulators for approval this year have been thrown into doubt after the Regeneron-partnered drug failed one of a pair of phase 3 chronic obstructive ...